Cargando…

A meaningful exploration of ofatumumab in refractory NMOSD: a case report

OBJECTIVE: To report the case of a patient with refractory neuromyelitis optica spectrum disorder (NMOSD), who, despite showing poor response or intolerance to multiple immunosuppressants, was successfully treated with Ofatumumab. CASE PRESENTATION: A 42-year-old female was diagnosed with NMOSD in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhan, Yibo, Zhao, Min, Li, Xiaojun, Ouyang, Huiying, Du, Chenghao, Chen, Guixian, Lou, Zhenzhen, Chen, Haoxuan, Zhao, Yuanqi, Xu, Haoyou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337780/ https://www.ncbi.nlm.nih.gov/pubmed/37449206 http://dx.doi.org/10.3389/fimmu.2023.1208017

Ejemplares similares

The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study
por: Li, Xiaojun, et al.
Publicado: (2022)

Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy
por: Cao, Shugang, et al.
Publicado: (2023)

Refractory pemphigus vulgaris successfully treated with ofatumumab
por: Klufas, Daniel M., et al.
Publicado: (2020)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Impaired Meningeal Lymphatic Flow in NMOSD Patients With Acute Attack
por: Wang, Xinxin, et al.
Publicado: (2021)

Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients
por: Yao, Xiao-Ying, et al.
Publicado: (2022)

Atezolizumab-associated encephalitis in metastatic breast cancer: A case report
por: Chen, Guixian, et al.
Publicado: (2022)

Ofatumumab Desensitization Protocol: A Case of Refractory Immune Thrombocytopenic Purpura
por: Cochran, Audra L, et al.
Publicado: (2023)

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration
por: Torres, Julia Baguña, et al.
Publicado: (2022)

The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab
por: Zhang, Rui, et al.
Publicado: (2023)

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
por: Faissner, Simon, et al.
Publicado: (2022)

The First Case Report of Preschool-Onset SS/SLE Coexisting With NMOSD of Chinese Origin
por: Liu, Liqun, et al.
Publicado: (2022)

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
por: Castro, J E, et al.
Publicado: (2014)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
por: Carnero Contentti, Edgar, et al.
Publicado: (2021)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Protecting effect of emodin in experimental autoimmune encephalomyelitis mice by inhibiting microglia activation and inflammation via Myd88/PI3K/Akt/NF-κB signalling pathway
por: Zheng, Kenan, et al.
Publicado: (2022)

Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys
por: Theil, Diethilde, et al.
Publicado: (2019)

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
por: Scarfò, Lydia, et al.
Publicado: (2022)

Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review
por: Chen, Bo, et al.
Publicado: (2021)

Ofatumumab for the treatment of refractory anti‐LGI1 encephalitis with long‐term poor blood glucose control in type 1 diabetes
por: Chen, Kaili, et al.
Publicado: (2023)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
por: Shi, Mingchao, et al.
Publicado: (2022)

Facial-Onset Sensory Motor Neuronopathy Syndrome is not Always Facial Onset
por: Zhang, Weijun, et al.
Publicado: (2020)

Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
por: Luo, Chengxin, et al.
Publicado: (2023)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease (MOGAD)
por: Hiya, Satomi, et al.
Publicado: (2023)

Blood pressure and body fat percent in women with NMOSD
por: Chen, Xiaohong, et al.
Publicado: (2019)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

Nutzen der frühzeitigen Behandlung mit Ofatumumab bestätigt
por: Linder, Isabelle
Publicado: (2022)

Lupus and NMOSD: The Blending of Humoral Autoimmunity
por: Ochi, Maria Goretti S., et al.
Publicado: (2020)

Epidemiology of Pediatric NMOSD in Germany and Austria
por: Lechner, Christian, et al.
Publicado: (2020)

Contemporary management challenges in seropositive NMOSD
por: Costello, Fiona, et al.
Publicado: (2022)

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia
por: Hatswell, Anthony J., et al.
Publicado: (2017)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pger5e9vdluurjujejkcukvc2j